OIG: Medicaid Paid $6.2B for Unapproved Drugs
OIG recommended that the FDA conduct frequent reviews of the NDC Directory to ensure its accuracy and thoroughness, and work with the Centers for Medicare & Medicaid Services and Congress to create legislative or regulatory changes that force drug makers to list all approved products with FDA before they're eligible for Medicaid payments.
In its formal response to the audit, FDA said it generally agreed with the OIG's recommendations, and had already begun implementing several initiatives to evaluate and enhance the quality of drug listing data.
CMS Paid $112M for Potentially Harmful Drugs, OIG Says
OIG: Medicare Contractor Overpaid $39.2 Million for Diabetic's Supplies
OIG: Feds Paid $43.3 Million for Possibly Ineffective Drugs
OIG: Medicare Paid $1.2 Billion For Drugs With Invalid Prescriber Numbers
John Commins is a senior editor with HealthLeaders Media.
- Providers Prep for New Payment Models as Population Health Grows
- CMS Mulls Income-Adjusting MA Stars
- Transforming Decision Support and Reporting
- 3 Ways to Rev Employee Development Programs
- Nurse Ethics Comes to a Head at Guantanamo Bay
- In Lakeport, CA, a Population Health Laboratory is Born
- Providers' Push to Consolidate Roils Payers
- As Retail Clinics Surge, Quality Metrics MIA
- Aligning Executive Compensation with Provider Mission
- No Employee Satisfaction, No Patient-Centered Culture